Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHenan Institute of Cardiovascular Epidemiology

About this trial

At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.

Eligibility criteria

Qualifiers

Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the "Global Unified Definition of Fourth Myocardial Infarction"

Disqualifiers

The patients could not tolerate RIPC or RIPerC

Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases

The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively

severe liver dysfunction (bilirubin > 20 mmol / L, prothrombin time > 2.0 ratio)

Trial design

Treatments tested in this trial

  • RIPerC
  • RIPC

Treatment groups

2,146 Participants
are divided into 3 treatment groups